Compare SWMR & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWMR | CRMD |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.9M | 509.9M |
| IPO Year | 2026 | 2009 |
| Metric | SWMR | CRMD |
|---|---|---|
| Price | $39.31 | $7.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.20 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.55 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $25.75 | $6.13 |
| 52 Week High | $68.97 | $17.43 |
| Indicator | SWMR | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 58.47 |
| Support Level | N/A | $6.14 |
| Resistance Level | $68.97 | $7.44 |
| Average True Range (ATR) | 9.08 | 0.24 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 32.13 | 82.97 |
Swarmer Inc is a provider of autonomous drone swarm software and AI solutions, specializing in vendor-agnostic technologies. It develops software platforms and artificial intelligence systems for defence applications, enabling military organisations to deploy and coordinate large-scale unmanned and autonomous systems. Its offerings include swarm coordination software, multi-domain unmanned systems integration, collaborative autonomy solutions, and command-and-control software for distributed robotic operations. Its key software and AI systems include: i) STYX AI Command & Control System, ii) MINAS Autonomy and Collaboration AI and iii) TRIDENT Embedded Drone Operating System. The company generates revenue through software license sales.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.